Monopost (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary body, promoting remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced drainage lowers intraocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Monopost is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the clinician’s instructions.

Safety of latanoprost in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Monopost product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monopost (latanoprost) belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker eye drops such as timolol, latanoprost often provides greater pressure reduction with a different side‑effect profile, making it a common first‑line option.

Monopost should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from light and moisture, and do not freeze the product.

Monopost is administered as a topical ocular drop. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the prescribed eye(s) without touching the bottle tip to the eye.

Serious risks, although rare, include severe allergic reactions, uveitis, macular edema, and a paradoxical increase in intraocular pressure. Patients should seek immediate medical attention if they experience significant eye pain, vision changes, swelling, or signs of an allergic response.

Monopost should not be used by individuals with known hypersensitivity to latanoprost or any excipients in the formulation, and it is contraindicated in patients with active intraocular inflammation such as iritis or uveitis. A thorough ophthalmic evaluation is required before initiating therapy.